Pembrolizumab-related autoimmune hemolytic anemia in a patient with metastatic lung adenocarcinoma: a case report
Open Access
- 31 October 2021
- journal article
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 38 (4), 366-370
- https://doi.org/10.12701/yujm.2021.00899
Abstract
Immune checkpoint inhibitors (ICIs) have become the main drugs for programmed cell death receptor-1 or ligand-1 expressing non-small cell lung cancer (NSCLC) combined with conventional chemotherapy. ICIs are generally more tolerable than cytotoxic chemotherapies in terms of toxicity, and ICI-related adverse events are mild and manageable. However, these drugs may lead to unexpected severe adverse events such as immune-related hematologic toxicities, which could be life-threatening. Here, a rare case of a pembrolizumab-related adverse event in a patient with NSCLC who showed early-onset hemolytic anemia and recovered by high-dose steroid and a series of plasma exchanges is reported.Keywords
This publication has 17 references indexed in Scilit:
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced MelanomaJournal of Clinical Oncology, 2017
- Autoimmune Hemolytic Anemia as a Complication of Nivolumab TherapyCase Reports in Oncology, 2016
- Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanomaMelanoma Research, 2016
- Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell AplasiaThe New England Journal of Medicine, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- The Clinical Pictures of Autoimmune Hemolytic AnemiaTransfusion Medicine and Hemotherapy, 2015
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaClinical Therapeutics, 2015
- Tumor Immunotherapy Directed at PD-1The New England Journal of Medicine, 2012
- Cancer immunotherapy comes of ageNature, 2011